Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, parallel-group study conducted under in-house blinding conditions to determine the safety, tolerability and efficacy of aprepitant regimen compared to ondansetron regimen for the prevention of chemotherapy induced nausea and vomiting (CINV) associated with high dose cisplatin in cycle 1

Next Previous
X
Search
Trial Profile

A randomized, double-blind, parallel-group study conducted under in-house blinding conditions to determine the safety, tolerability and efficacy of aprepitant regimen compared to ondansetron regimen for the prevention of chemotherapy induced nausea and vomiting (CINV) associated with high dose cisplatin in cycle 1

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Ondansetron; Ondansetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 26 Jan 2010 Company added as trial affiliate, primary endpoint identified as Patient vomiting as reported by ClinicalTrials.gov.
    • 16 Sep 2008 Results presented at ESMO
    • 31 Aug 2006 Status change

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top